Clinical Trial Update: Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies [Phase 2]

View source ↗

Summary

Phase 2 trial assessing cognitive effects of the oral p38 alpha kinase inhibitor neflamapimod in dementia with Lewy bodies has completed; results posted in 2021…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dementia with Lewy Bodies

Drugs mentioned

• Neflamapimod (neflamapimod)

Snippet

Sponsor: EIP Pharma Inc | Conditions: Dementia With Lewy Bodies (DLB) | Phase 2 | Status: COMPLETED | Results posted: 2021-11-02